Studies on sensitivity of zebrafish as a model organism for Parkinson's disease: Comparison with rat model

被引:34
作者
Makhija, Dinesh T. [1 ]
Jagtap, Aarti G. [1 ]
机构
[1] Bombay Coll Pharm, Dept Pharmacol, Mumbai 400098, Maharashtra, India
关键词
Catalepsy; 3-[4,5-dimethylthia zol-2-yl]-2,5-diphenyltetrazolium bromide; zebrafish;
D O I
10.4103/0976-500X.124422
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To determine the utility of zebra fish as an animal model for Parkinson's disease (PD) in comparison with rat model. Materials and Methods: MTT assay was performed on rat and zebrafish brain synaptosomal fractions using rotenone as a neurotoxic agent. Quercetin and resveratrol were used as standards to compare anti-apoptotic activity in both organisms. Catalepsy was induced in zebrafish by exposing them to haloperidol (9 pM) solution. Drug-treated groups were exposed to bromocriptine and pramipexole, 30 min prior to haloperidol exposure at the dose of 2, 5, and 10 ptg/mL. Swimming speed, time spent in the bottom of the tank, and complete cataleptic time were evaluated to assess behavioral changes. In rats, catalepsy was induced using haloperidol (1.25 mg/kg i. p.). Drug-treated groups received bromocriptine (2.5 mg/kg.) and pramipexole (1 mg/kg) orally. Bar test, block test, and locomotor activity were carried out to assess behavioral changes. Results: Resveratrol and quercetin showed comparable inhibition of apoptosis in rats and zebrafish. In anti-cataleptic study, bromocriptine and pramipexole-treated groups showed significant difference (P < 0.05) in behavioral parameters as compared to haloperidol control group in both the experimental organisms. Results obtained from fish model were in correlation with rat model. Conclusion: Findings of the present study revealed that zebrafish model is highly sensitive and can be used for basic screening of drugs against PD.
引用
收藏
页码:39 / 46
页数:8
相关论文
共 25 条
[1]   Loss of PINK1 function affects development and results in neurodegeneration in zebrafish [J].
Anichtchik, Oleg ;
Diekmann, Heike ;
Fleming, Angeleen ;
Roach, Alan ;
Goldsmith, Paul ;
Rubinsztein, David C. .
JOURNAL OF NEUROSCIENCE, 2008, 28 (33) :8199-8207
[2]   Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery [J].
Barros, T. P. ;
Alderton, W. K. ;
Reynolds, H. M. ;
Roach, A. G. ;
Berghmans, S. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) :1400-1413
[3]  
Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7
[4]   Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes [J].
Bishnoi, Mahendra ;
Chopra, Kanwaljit ;
Kulkarni, Shrinivas K. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 552 (1-3) :55-66
[5]   Classic and New Animal Models of Parkinson's Disease [J].
Blesa, Javier ;
Phani, Sudarshan ;
Jackson-Lewis, Vernice ;
Przedborski, Serge .
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2012,
[6]  
Box J, 2005, NEURORX, V2, P414
[7]   Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease [J].
Bretaud, S ;
Lee, S ;
Guo, S .
NEUROTOXICOLOGY AND TERATOLOGY, 2004, 26 (06) :857-864
[8]  
Echevarria DJ., 2008, WATER AIR SOIL POLL, V21, P19, DOI [10.46867/ijcp.2008.21.01.02, DOI 10.46867/IJCP.2008.21.01.02]
[9]   Zebrafish as a new animal model for movement disorders [J].
Flinn, Laura ;
Bretaud, Sandrine ;
Lo, Christine ;
Ingham, Phillip W. ;
Bandmann, Oliver .
JOURNAL OF NEUROCHEMISTRY, 2008, 106 (05) :1991-1997
[10]   Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio) [J].
Flinn, Laura ;
Mortiboys, Heather ;
Volkmann, Katrin ;
Koester, Reinhard W. ;
Ingham, Phillip W. ;
Bandmann, Oliver .
BRAIN, 2009, 132 :1613-1623